The human recombinant histamine releasing factor: functional evidence that it does not bind to the IgE molecule.
BACKGROUND
We have previously shown that the human recombinant histamine releasing factor (HrHRF) caused histamine release from a subset of basophils from donors with allergy, and this release seemed to be dependent on the presence of a certain type of IgE, termed IgE+. IgE molecules that did not support HrHRF-induced histamine release were termed IgE-. However, subsequently we demonstrated that HrHRF primes anti-IgE-antibody-induced histamine release from all basophils, irrespective of the type of IgE on the cell surface.


OBJECTIVE
Because these data suggested that HrHRF does not exert its biologic effects by binding to IgE, but rather that it interacted with a surface receptor on the basophil, we wanted to obtain functional evidence that HrHRF did or did not bind to the IgE molecule.


METHODS
The rat basophilic leukemia cell line (RBL-SX38), which has been transfected to express a functional human FcepsilonRI (alpha-, beta-, and gamma-chains of the receptor) in addition to the normal rat FcepsilonRI, was used. The presence of the human FcepsilonRI receptor enables these cells to be sensitized with human IgE. Cells were passively sensitized with 1000 ng/mL human IgE+ or 1000 ng/mL human IgE- for 60 minutes at 37 degrees C. Unsensitized cells served as a control. After the cells were washed, 1 x l0(5) cells were stimulated in the presence of 1 mmol/L Ca2+ with 0.1 microg/mL anti-IgE, 40 microg/mL HrHRF, or 40 microg/mL mouse recombinant HRF (MrHRF), which has 96% homology to HrHRF.


RESULTS
Mean anti-IgE-induced histamine release was 33% +/- 15%, and there was no difference between IgE+ sensitization (32% +/- 12%) and IgE- sensitization (34% +/- 18%). However, in contrast to human basophil experiments, neither HrHRF (0% +/- 0%) nor MrHRF (3% +/- 5%) caused histamine release in RBL cells sensitized with IgE+. In addition, priming the transfected RBL-SX38 cells or the parental cell line, RBL-2H3 cells, with HrHRF or MrHRF did not increase anti-IgE-induced histamine release.


CONCLUSIONS
The results indicate that HrHRF does not bind to IgE, either IgE+ or IgE-. Therefore it appears likely that rHRF signals through its own specific receptor, which is not expressed or functional on RBL-SX38 or RBL-2H3 cells, but which seems to be expressed on basophils of atopic and nonatopic donors.
Wantke
F
F
Johns Hopkins Asthma & Allergy Center, Baltimore, MD 21224, USA.
MacGlashan
D W
DW
Langdon
J M
JM
MacDonald
S M
SM
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D001491:Basophils / Q000276:immunology / Q000378:metabolism*; D014408:Biomarkers, Tumor; D004306:Dose-Response Relationship, Immunologic; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology* / Q000378:metabolism*; D008222:Lymphokines / Q000276:immunology / Q000378:metabolism* / Q000494:pharmacology; D051379:Mice; D051381:Rats; D017455:Receptors, IgE / Q000378:metabolism; D011994:Recombinant Proteins / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D000090324:Tumor Protein, Translationally-Controlled 1
D000888:Antibodies, Anti-Idiotypic; D014408:Biomarkers, Tumor; D008222:Lymphokines; D017455:Receptors, IgE; D011994:Recombinant Proteins; D000090324:Tumor Protein, Translationally-Controlled 1; D007073:Immunoglobulin E